|
Jan 12
|
16 Best Mid-Cap Growth Stocks To Buy Now
|
|
Jan 10
|
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
|
|
Jan 3
|
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
|
|
Dec 26
|
13 High Growth Healthcare Stocks to Buy
|
|
Dec 18
|
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
|
|
Dec 5
|
12 Most Promising Stocks to Buy According to Hedge Funds
|
|
Dec 5
|
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
Nov 9
|
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
|
|
Nov 4
|
Estimating The Fair Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
|
|
Sep 8
|
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 7
|
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Sep 6
|
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
|
|
Aug 9
|
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
|
|
Apr 27
|
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
|